Too busy to save time? Why IP teams can’t afford to wait on AI

In-house counsel from AstraZeneca, BAT and Novartis say that investing in AI now will pay off in time saved, but warn that tools remain prone to ‘confident’ errors, writes Marisa Woutersen.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

European patent offices raise fees

2 April 2026 Two of Europe’s most important IP offices have implemented fee increases this month, with some long-standing UK charges, dating back to the late 1990s, finally seeing a rise.

Europe

UPC refuses early knockout in Illumina–Element dispute

2 April 2026 A Lisbon judge rejects a bid to strike out the case over a drafting issue, offering insight into the court’s high bar for early dismissal.

Europe

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

30 March 2026 Judges found no reason to set aside provisional measures issued by a local division, following a challenge from Sinocare and A Menarini Diagnostics.

More features

European patent offices raise fees

UPC refuses early knockout in Illumina–Element dispute

Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market

IndiaMart v CDSCO: A test of intermediary liability

UPC appeals court upholds Abbott injunction in glucose monitoring patent dispute

CRISPR priority feud ends at USPTO as board reaches decision

Novartis bets $2bn on biologics as Xolair patents fade

WIPR debuts Global In-House Elite 2026

Too busy to save time? Why IP teams can’t afford to wait on AI

More on this story

Editor's picks

Editor's picks

More features